Company: TXG
Filing Date: 2025-11-07
Form Type: 10-Q
Source: 0001628280-25-050332
Chunk: 4

Company: 10x Genomics, Inc.
Filing Date: 2025-11-07
Form: 10-Q
Item: Part I, Item 1
Chunk 4
---
Net loss$(27,472)$(35,753)$(27,292)$(133,599)Other comprehensive income (loss), net of tax:Unrealized gains (losses) on available-for-sale marketable securities(1)3 (18)188 Realized loss on available-for-sale marketable securities reclassified into net loss— 3 — 3 Foreign currency translation adjustment(81)456 649 270 Other comprehensive income (loss), net of tax(82)462 631 461 Comprehensive loss$(27,554)$(35,291)$(26,661)$(133,138)

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

5

10x Genomics, Inc.

Condensed Consolidated Statements of Stockholders’ Equity

(Unaudited)

(In thousands, except share data)Common StockAdditional Paid-inCapitalAccumulatedDeficitAccumulatedOther ComprehensiveIncome (Loss)TotalStockholders’EquitySharesAmountBalance as of December 31, 2024122,291,837 $2 $2,177,672 $(1,467,047)$(493)$710,134 Issuance of Class A common stock related to equity awards841,913 — 422 — — 422 Stock-based compensation— — 30,571 — — 30,571 Net loss— — — (34,358)— (34,358)Other comprehensive income— — — — 126 126 Balance as of March 31, 2025123,133,750 $2 $2,208,665 $(1,501,405)$(367)$706,895 Issuance of Class A common stock related to equity awards1,308,382 — 3,522 — — 3,522 Stock-based compensation— — 27,737 — — 27,737 Net income— — — 34,538 — 34,538 Other comprehensive income— — — — 587 587 Balance as of June 30, 2025124,442,132 $2 $2,239,924 $(1,466,867)$220 $773,279 Issuance of Class A common stock related to equity awards997,422